SCHEMBL15964228

SCHEMBL15964228

CNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCCCC3)cc2OC)ncc1C(F)(F)F

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 16/20 0.85
MAPK9 P45984 14/20 0.85
PTK2 Q05397 5/20 0.85
CDC7 O00311 1/20 0.53
PLK4 O00444 1/20 0.53
CHEK1 O14757 1/20 0.53
AURKA O14965 1/20 0.53
DCLK1 O15075 1/20 0.53
PDPK1 O15530 1/20 0.53
DAPK3 O43293 1/20 0.53
DYRK3 O43781 1/20 0.53
JAK2 O60674 1/20 0.53
PRKD3 O94806 1/20 0.53
PAK4 O96013 1/20 0.53
CHEK2 O96017 1/20 0.53
EGFR P00533 1/20 0.53
ERBB2 P04626 1/20 0.53
PRKCG P05129 1/20 0.53
INSR P06213 1/20 0.53
LCK P06239 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1231714 0.93 MAPK10 (0.84) MAPK10MAPK9PTK2ALK
SCHEMBL25270760 0.93 MAPK10 (0.84) MAPK10MAPK9PTK2EGFRALK
Vs-4718 SCHEMBL47360 0.92 MAPK10 (1.00) MAPK10MAPK9PTK2CDC7PLK4
Vs-4718 SCHEMBL29381276 0.92 MAPK10 (1.00) MAPK10MAPK9PTK2CDC7PLK4
Vs-4718 SCHEMBL29478885 0.92 MAPK10 (1.00) MAPK10MAPK9PTK2CDC7PLK4
Vs-4718 SCHEMBL29493098 0.92 MAPK10 (1.00) MAPK10MAPK9PTK2CDC7PLK4
SCHEMBL25228904 0.91 MAPK10 (0.82) MAPK10MAPK9PTK2CDC7PLK4
Vs-4718 SCHEMBL30354503 0.91 PTK2 (1.00) MAPK10MAPK9PTK2CDC7PLK4
SCHEMBL26184016 0.91 MAPK10 (0.82) MAPK10MAPK9PTK2CDC7PLK4
SCHEMBL12887672 0.91 MAPK10 (0.72) MAPK10MAPK9PTK2JAK2IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9505719-B2 Synthesis and use of kinase inhibitors VERASTEM, INC. (US) 2016-11-29 US disclosed
US-20140235635-A1 SYNTHESIS AND USE OF KINASE INHIBITORS PONIARD PHARMACEUTICALS, INC (US) 2014-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235635-A1 SYNTHESIS AND USE OF KINASE INHIBITORS PTK2, FYN, LCK MAPK10 126/4885MAPK9 89/4885PTK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.